

INTRODUCTION .....	XV
STUDY GOAL AND OBJECTIVES .....	XV
REASONS FOR DOING THE STUDY .....	XVI
CONTRIBUTION OF THE STUDY AND FOR WHOM .....	XVII
SCOPE AND FORMAT .....	XVII
METHODOLOGY .....	XVIII
INFORMATION SOURCES .....	XVIII
RELATED BCC REPORTS .....	XIX
AUTHOR'S CREDENTIALS .....	XIX
BCC ON-LINE SERVICES.....	XIX
 SUMMARY.....	 XXI
<i>SUMMARY TABLE U.S. MARKET FOR IN VITRO TOXICOLOGY, THROUGH 2007</i> (\$ MILLIONS) .....	 XXII
<i>SUMMARY FIGURE U.S. MARKET FOR IN VITRO TOXICOLOGY, 2002 AND 2007</i> (\$ MILLIONS) .....	 XXII
 INDUSTRY STRUCTURE .....	 1
INTRODUCTION .....	1
THE CLASSIFICATION PROBLEM OF <i>IN VITRO</i> TOXICOLOGY .....	2
SUPPLIES FOR <i>IN VITRO</i> TOXICOLOGY .....	3
PRODUCERS OF GOODS AND SERVICES USED <i>IN VITRO</i> TOXICOLOGY TESTING .....	4
TABLE 1 DEDICATED AND NON-DEDICATED FIRMS IN <i>IN VITRO</i> TOXICOLOGY .....	4
TABLE 2 BREAKDOWN OF PRODUCTS AND SERVICES IN <i>IN VITRO</i> TOXICOLOGY.....	5
TABLE 3 LIST OF SUPPLIERS FOR <i>IN VITRO</i> TOXICOLOGICAL PRODUCTS*.....	6
MANUFACTURERS OF GOODS USED IN <i>IN VITRO</i> TOXICOLOGY TESTING.....	6
Producers of Organotypic Human Skin and Similar Products .....	7
A Brief History of Organotypic Skin Production .....	7
Current Producers .....	8
TABLE 4 OPEN PRODUCERS OF ORGANOTYPIC SKIN AND CORROSIVE TEST KITS FOR <i>IN VITRO</i> TOXICOLOGY .....	8
The Captive Market for Organotypic Skin Products.....	9
TABLE 5 CAPTIVE PRODUCERS OF ORGANOTYPIC HUMAN SKIN OR SIMILAR GOODS .....	9
Trends in the Industry .....	10
Product Development.....	10
Captive versus Open .....	11
Producers of Cell Lines for <i>In Vitro</i> Toxicology .....	11
TABLE 6 PRODUCERS OF CELL LINES FOR <i>IN VITRO</i> TOXICOLOGY.....	11
Databases.....	12
TABLE 7 DATABASE PROVIDERS FOR TOXICOGENOMICS.....	12

CORPORATIONS PROVIDING <i>IN VITRO</i> TOXICOLOGY SERVICES.....	13
OPEN PRODUCERS OF <i>IN VITRO</i> TOXICOLOGY .....	13
<i>TABLE 8 SOME U.S. FIRMS THAT PROVIDE IN VITRO TOXICOLOGICAL</i>	
<i>RESEARCH/TESTING CONTRACT SERVICES</i> .....	14
CAPTIVE PRODUCTION OF <i>IN VITRO</i> TOXICOLOGICAL	
RESEARCH.....	15
Pharmaceutical Industries/Biotech .....	15
Structure of the Industry.....	16
<i>TABLE 9 THE STRUCTURE OF THE BIOTECH/PHARMACEUTICAL INDUSTRY</i> .....	16
Trends in the Pharma/Biotech Industry .....	17
Mergers and Acquisitions.....	17
The Drug Development Process: Developing a New	
Medical Entity (NME) .....	18
Costs of Drug Development.....	18
Outsourcing in the Biotech/Pharma Industry .....	19
Outsourcing Toxicity Testing .....	20
<i>TABLE 10 PERCENTAGE OF IN VITRO TOXICOLOGY OUTSOURCED IN THE</i>	
<i>PHARMACEUTICAL BIOTECH INDUSTRY, 2002</i> .....	20
Outsourcing in Predictive Toxicology .....	20
Outsourcing in Late Stage Mutagenesis	
Testing.....	21
<i>TABLE 11 FIRMS INVOLVED IN LATE STAGE MUTAGENESIS TESTING</i> .....	21
Outsourcing in Investigative Toxicology .....	21
Overall Outsourcing.....	22
PERSONAL CARE/HOUSEHOLD GOODS .....	22
<i>TABLE 12 PERSONAL CARE COMPANIES WITH MAJOR EFFORTS IN IN VITRO</i>	
<i>TOXICOLOGY</i> .....	23
Outsourcing in Personal Care .....	23
COSMETICS .....	23
<i>TABLE 13 COSMETICS COMPANIES WITH MAJOR EFFORTS IN IN VITRO</i>	
<i>TOXICOLOGY</i> .....	24
INDUSTRY ORGANIZATIONS .....	25
CIIT .....	25
CIIT's Three-fold Mission.....	25
CIIT's Three-Fold Mission (Continued) .....	26
<i>TABLE 14 LIST OF CIIT MEMBER COMPANIES IN 2001</i> .....	27
<i>TABLE 15 INDIVIDUAL SPONSORS FOR CIIT, 2001</i> .....	28
COMPANY PROFILES .....	29
ATCC .....	29
XENOMETRIX.....	30
CLONETICS .....	30
MOLECULAR TOXICOLOGY, INC. ....	30
IN VITRO TECHNOLOGIES.....	31
BRISTOL MYERS/SQUIBB .....	31
MERCK & CO., INC. ....	32
PROCTER & GAMBLE .....	32

NAMSA.....	33
INVITRO INTERNATIONAL .....	34
MATTEK CORP. ....	34
COLGATE-PALMOLIVE.....	35
BIORELIANCE .....	35
SITEK RESEARCH LABORATORIES.....	36
INSTITUTE FOR IN VITRO SCIENCES, INC.....	36
ICONIX PHARMACEUTICALS, INC.....	36
NOVARTIS INTERNATIONAL AG.....	37
AVENTIS.....	37
ASTRA-ZENECA .....	38
GOVERNMENT REGULATION .....	39
A BRIEF HISTORY OF <i>IN VITRO</i> TOXICOLOGY IN THE U.S.	
GOVERNMENT.....	39
THE NATIONAL TOXICOLOGY PROGRAM .....	40
NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH	
SCIENCES (NIEHS) .....	41
NTP METHODOLOGY.....	42
TABLE 16 NOMINATION PRINCIPLES FOR NTP STUDIES .....	42
ICCVAM.....	43
TABLE 17 LIST OF FEDERAL AGENCIES THAT PARTICIPATE IN ICCVAM.....	44
TABLE 18 GOALS OF ICCVAM .....	44
TABLE 19 CURRENT RESEARCH OF ICCVAM.....	45
Up and Down Testing.....	45
Corrositex Assay, Epiderm, Episkin and Rat Skin	
Transcutaneous Electrical Resistance (TER) Assays .....	46
FETAX and <i>in Vitro</i> Endocrine Disruptor Screening	
Assays .....	46
LLNA.....	46
EpiOcular.....	47
<i>In Vitro</i> 3T3 NRU Phototoxicity Test Method.....	47
AGENCY FOR TOXIC SUBSTANCES AND DISEASE REGISTRY	
(ATSDR) .....	47
UNITED STATES DEPARTMENT OF AGRICULTURE (USDA).....	48
ENVIRONMENTAL PROTECTION AGENCY (EPA).....	48
CONSUMER PRODUCTS SAFETY COMMISSION (CPSC).....	49
FOOD AND DRUG ADMINISTRATION (FDA) .....	49
FOOD AND DRUG ADMINISTRATION (FDA) (CONTINUED) .....	50
FOOD AND DRUG ADMINISTRATION (FDA) (CONTINUED) .....	51
EUROPEAN GOVERNMENT AGENCIES.....	52
TABLE 20 COMPARISON BETWEEN U.S. AND EUROPEAN GOVERNMENTAL	
APPROACHES TO <i>IN VITRO</i> TOXICOLOGY.....	52
PRIMARY ORGANIZATIONS.....	53
GOALS.....	53
ABOUT ZEBET .....	53

CORPORATE INVOLVEMENT .....	53
OVERALL PROGRESS.....	54
PRODUCTS .....	55
THE INFORMATION OF <i>IN VITRO</i> TOXICOLOGY.....	55
<i>IN VITRO</i> TOXICOLOGY IN THE PHARMACEUTICAL	
INDUSTRY.....	56
TABLE 21 THE DRUG DEVELOPMENT PROCESS.....	57
A Brief History of <i>In Vitro</i> Toxicology in Early Drug	
Candidate Evaluations.....	57
The Rise of Predictive Toxicology .....	58
TABLE 22 REQUIREMENTS FOR PREDICTIVE TOXICOLOGY SCREENS.....	58
Speed and Reliability.....	59
Inexpensive .....	59
Sensitivity .....	60
Current Predictive Screening Technology .....	60
Cell Types.....	60
TABLE 23 BREAKDOWN OF THE U.S. PREDICTIVE TOXICOLOGY MARKET BY	
TYPE, THROUGH 2007 (\$ MILLIONS) .....	61
The Three Questions Asked in Predictive	
Toxicology Concerning Hepatocytes .....	61
TABLE 24 EVALUATION OF HEPATOCYTES FOR <i>IN VITRO</i> TOXICOLOGY.....	61
Hepatotoxicity.....	62
Changes in Metabolism .....	62
Changes in P450 Metabolism .....	62
Growth Rates of Predictive Toxicology .....	63
New Gene Chip Technology .....	64
TABLE 25 CURRENT AND DEVELOPMENTAL GENE CHIP TECHNOLOGY.....	64
Producers of Currently Available Technology .....	64
Competing Technology.....	65
Number of Genes and the Analysis Problem.....	65
Utility of these Approaches .....	66
LATE STAGE MUTAGENESIS TESTING .....	67
TABLE 26 TYPES OF LATE STAGE MUTAGENESIS TESTING .....	68
Type 1 Testing .....	68
Type 2 Testing .....	68
Type 3 Testing .....	69
TABLE 27 INCREASED RESISTANCE OF WHOLE ANIMALS COMPARED TO	
CELLS.....	70
Metabolism.....	70
Cytotoxicity Repair Mechanisms .....	71
DNA Repair Mechanisms .....	71
Types of Animals .....	71
Markets for Late Stage Mutagenesis Testing .....	72
TABLE 28 U.S. MARKETS FOR LATE STAGE MUTAGENESIS TESTING,	
THROUGH 2007.....	72

FIGURE 1 U.S. MARKETS FOR LATE STAGE MUTAGENESIS TESTING, 2002 AND 2007 (\$ MILLIONS).....	73
INVESTIGATIVE TOXICOLOGY.....	73
The “Classical” Approach .....	74
Toxicogenomics .....	75
Requirements for Toxicogenomics.....	76
Costs of this Research.....	77
TABLE 29 COST OF EVALUATING COMPOUNDS USING CHEMOGENOMICS .....	77
TABLE 30 U.S. MARKETS FOR INVESTIGATIVE TOXICOLOGY, THROUGH 2007 (\$ MILLIONS).....	78
FIGURE 2 U.S. MARKETS FOR INVESTIGATIVE TOXICOLOGY, 2002 AND 2007 (\$ MILLIONS).....	78
OVERALL SPENDING ON <i>IN VITRO</i> TOXICOLOGY IN THE PHARMACEUTICAL INDUSTRY.....	79
TABLE 31 MARKETS FOR <i>IN VITRO</i> TOXICOLOGY IN THE PHARMACEUTICAL INDUSTRY, THROUGH 2007 (\$ MILLIONS).....	79
FIGURE 3 MARKETS FOR <i>IN VITRO</i> TOXICOLOGY IN THE PHARMACEUTICAL INDUSTRY, 2002 AND 2007 (\$ MILLIONS).....	80
<i>IN VITRO</i> TOXICOLOGY TESTING IN COSMETICS, PERSONALCARE/ HOUSEHOLD GOODS, AND INDUSTRY .....	80
PERSONAL CARE/HOUSEHOLD GOODS AND COSMETICS.....	81
<i>In Vitro</i> and Clinical Testing.....	81
TABLE 32 TYPES OF TESTING IN THE PERSONAL CARE/HOUSEHOLD GOODS AND COSMETIC INDUSTRY.....	82
Government Agency Approval .....	82
Minor Formulation Changes.....	83
Paper Toxicology.....	83
Paper Toxicology (Continued) .....	84
Major Changes in Formulation.....	85
Markets for <i>In Vitro</i> Toxicology Testing.....	85
TABLE 33 U.S. MARKETS FOR <i>IN VITRO</i> TOXICOLOGY IN PERSONAL CARE/ HOUSEHOLD GOODS AND COSMETICS, THROUGH 2007 (\$ MILLIONS).....	85
FIGURE 4 U.S. MARKETS FOR <i>IN VITRO</i> TOXICOLOGY IN PERSONAL CARE/ HOUSEHOLD GOODS AND COSMETICS, 2002 AND 2007 (\$ MILLIONS).....	86
Dermal and Ocular Testing.....	86
TABLE 34 U.S. MARKET FOR <i>IN VITRO</i> TOXICOLOGY TESTING BY TYPE IN PERSONAL CARE/HOUSEHOLD GOODS AND COSMETICS, THROUGH 2007 (\$ MILLIONS).....	86
FIGURE 5 U.S. MARKET FOR <i>IN VITRO</i> TOXICOLOGY TESTING BY TYPE IN PERSONAL CARE/HOUSEHOLD GOODS AND COSMETICS, 2002 AND 2007 (\$ MILLIONS).....	87
TABLE 35 U.S. MARKET FOR <i>IN VITRO</i> OCULAR TESTING BY TYPE IN PERSONAL CARE/HOUSEHOLD GOODS AND COSMETICS, THROUGH 2007 (\$ MILLIONS).....	87
FIGURE 6 U.S. MARKET FOR <i>IN VITRO</i> OCULAR TESTING BY TYPE IN PERSONAL CARE/HOUSEHOLD GOODS AND COSMETICS, 2002 AND 2007 (\$ MILLIONS).....	88
Applications of <i>In Vitro</i> Toxicology .....	88

TABLE 36 U.S. MARKET FOR IN VITRO TOXICOLOGY SAFETY TESTING/PRODUCT DEVELOPMENT COMPARED WITH VALIDATION, THROUGH 2007 (\$ MILLIONS).....	89
FIGURE 7 U.S. MARKET FOR IN VITRO TOXICOLOGY SAFETY TESTING/PRODUCT DEVELOPMENT COMPARED WITH VALIDATION, 2002 AND 2007 (\$ MILLIONS).....	89
INDUSTRIAL TESTING .....	90
TABLE 37 U.S. MARKET FOR IN VITRO TOXICOLOGY SAFETY TESTING AND PRODUCT DEVELOPMENT IN INDUSTRY, THROUGH 2007 (\$ MILLIONS).....	91
FIGURE 8 U.S. MARKET FOR IN VITRO TOXICOLOGY SAFETY TESTING AND PRODUCT DEVELOPMENT IN INDUSTRY, 2002 AND 2007 (\$ MILLIONS).....	91
PRODUCTS USED FOR IN VITRO TOXICOLOGY .....	92
TABLE 38 U.S. MARKET FOR PRODUCTS USED FOR IN VITRO TOXICOLOGICAL TESTING, THROUGH 2007 (\$ MILLIONS).....	93
THE WELL-PUBLICIZED IN VITRO MARKET .....	93
FIGURE 9 U.S. MARKET FOR PRODUCTS USED FOR IN VITRO TOXICOLOGICAL TESTING, 2002 AND 2007 (\$ MILLIONS).....	94
CORROSIVITY TEST PRODUCTS.....	95
InVitro International's Corrositex .....	95
TABLE 39 ACCEPTANCE OF CORROSITEX BY GOVERNMENT AGENCIES .....	95
TABLE 40 COMPARISON OF CORROSITEX AND IN VIVO TESTING.....	96
COMPARING CORROSITEX AND IN VIVO TESTING .....	96
Applicability.....	97
Reproducibility.....	97
Pricing .....	98
MatTek's Corrosivity Test Products .....	98
DERMAL/OCULAR IN VITRO TEST PRODUCTS .....	98
Captive Products.....	99
InVitro International's Dermal/Ocular Products .....	100
Pricing .....	100
Applications for Dermal and Ocular Assays.....	101
TABLE 41 APPLICATIONS FOR IRRETECTION ASSAYS.....	101
MatTek's Dermal/Ocular Products .....	101
TABLE 42 COMPARISON BETWEEN MATTEK AND INVITRO INTERNATIONAL'S TECHNOLOGY.....	102
MatTek's Ocular Test Products .....	103
TABLE 43 SUBSTANCES THAT HAVE BEEN TESTED WITH EPIOCULAR .....	103
TABLE 43 (CONTINUED).....	104
MatTek's Epiderm .....	105
Materials Tested .....	105
TABLE 44 SUBSTANCES THAT HAVE BEEN TESTED WITH EPIDERM.....	105
TABLE 44 (CONTINUED).....	106
TABLE 44 (CONTINUED).....	107
Other Ocular and Dermal Tests .....	108
BCOP.....	108
HETCAM and CAMVA.....	108
MARKET APPLICATIONS.....	109
PHARMACEUTICAL/BIOTECH .....	109

PHARMACEUTICAL MARKET OVERVIEW.....	110
Market Forces in the Biotech/Pharma Industry .....	110
Increasing Price Pressure.....	110
Increased Competition in the	
Biotech/Pharmaceutical Arena .....	111
Generic Drug Development.....	111
Increased Number of Competitors.....	112
The Blockbuster Drug Development Model.....	113
Problems with the Blockbuster Model .....	114
<i>TABLE 45 PROBLEMS AND EFFECTS OF BLOCKBUSTER DRUG BUSINESS</i>	
<i>MODEL</i> .....	114
Saturation of Target Population.....	115
Limited Improvements Possible.....	115
<i>TABLE 46 R&amp;D SPENDING IN THE PHARMACEUTICAL INDUSTRY COMPARED</i>	
<i>WITH FDA APPROVALS, 1980-2002</i> .....	116
<i>FIGURE 10 R&amp;D SPENDING IN THE PHARMACEUTICAL INDUSTRY COMPARED</i>	
<i>WITH FDA APPROVALS, 1980-2002</i> .....	117
No Price Increases .....	117
No New Diseases .....	118
Cures for Chronic Ailments .....	118
Summary of these Trends .....	119
FUTURE TRENDS IN THE PHARMACEUTICAL INDUSTRY .....	119
Smaller Patient Populations .....	119
Increased Specificity of Drugs.....	119
Increased Pre-testing.....	120
The Changing Role of <i>In Vitro</i> Toxicology .....	121
Early Phase Discovery .....	121
The Rise of Combinatorial Chemistry.....	122
Efficacy .....	122
Toxicity .....	122
<i>TABLE 47 SPENDING ON IN VITRO TOXICOLOGY IN EARLY PHASE DRUG</i>	
<i>DEVELOPMENT, THROUGH 2007 (\$ MILLIONS)</i> .....	123
Late Stage Mutagenesis Testing.....	124
<i>TABLE 48 U.S. SPENDING ON IN VITRO TOXICOLOGY IN LATE STAGE</i>	
<i>MUTAGENECITY TESTING, THROUGH 2007 (\$ MILLIONS)</i> .....	124
Investigative Toxicology .....	125
<i>TABLE 49 U.S. MARKETS FOR INVESTIGATIVE TOXICOLOGY, THROUGH 2007</i>	
<i>(\$ MILLIONS)</i> .....	125
Trends Affecting Investigative Toxicology.....	126
<i>TABLE 50 REASONS FOR UNCERTAINTY IN THE PHARMACEUTICAL</i>	
<i>INDUSTRY</i> .....	126
POSSIBLE NEW PARADIGMS IN THE PHARMACEUTICAL	
INDUSTRY.....	127
<i>TABLE 51 PROBLEMS WITH THE USE OF COMBINATORIAL CHEMISTRY IN</i>	
<i>PHARMACEUTICALS</i> .....	127
Lots of Compounds .....	127
Determining Efficacy .....	128

Determining Toxicity.....	128
Data Analysis.....	129
Possible Future Trends .....	129
TABLE 52 POSSIBLE DIRECTIONS FOR <i>IN VITRO</i> TOXICOLOGY IN THE PHARMACEUTICAL INDUSTRY .....	130
THE COSMETICS AND PERSONAL CARE/HOUSEHOLD GOODS INDUSTRY .....	131
TABLE 53 U.S. MARKETS FOR <i>IN VITRO</i> TOXICOLOGY IN PERSONAL CARE/HOUSEHOLD GOODS AND COSMETICS, THROUGH 2007 (\$ MILLIONS) .....	132
COSMETICS FIRMS .....	132
The Rise of <i>In Vitro</i> Toxicology .....	132
<i>In Vitro</i> Toxicological Testing in the Cosmetics Industry.....	133
PERSONAL CARE/HOUSEHOLD GOODS .....	133
The Role of <i>In Vitro</i> Toxicology in Personal Care/Household Goods .....	134
TECHNOLOGY OVERVIEW .....	135
WHY USE <i>IN VITRO</i> TOXICOLOGY AT ALL?.....	135
TABLE 54 COMPARISON OF <i>IN VITRO</i> TOXICOLOGY WITH ANIMAL MODELS .....	135
APPLICABILITY.....	136
Animal Models .....	136
<i>In Vitro</i> Toxicology.....	137
REPRODUCIBILITY .....	137
COST.....	138
PUBLIC PERCEPTION.....	139
Mechanistic <i>In Vitro</i> Toxicology.....	139
<i>IN VITRO</i> TOXICOLOGY IN THE PHARMACEUTICAL INDUSTRY .....	140
TABLE 55 BROAD OUTLINE OF THE DRUG DEVELOPMENT PROCESS .....	141
PRE-CLINICAL DEVELOPMENT .....	141
CLINICAL DEVELOPMENT.....	142
FDA APPROVAL.....	142
A BRIEF HISTORY OF <i>IN VITRO</i> TOXICOLOGY IN DRUG DEVELOPMENT .....	143
Excretory and Pathway Metabolic Studies.....	144
Molecular Genetics Comes into Play.....	145
Fluorescent Probes Used for Investigative Toxicology.....	145
Confocal Microscopy.....	146
THE CHEMOGENOMICS REVOLUTION .....	147
Goals of Chemogenomic Toxicology .....	148
Pros and Cons of Chemogenomics .....	149
What Is Chemogenomics?.....	149
Pros of Chemogenomics .....	150
TABLE 56 GOALS OF CHEMOGENOMIC TOXICOLOGY IN DRUG DEVELOPMENT.....	151



	The Drug Development Process: The Discovery Funnel.....	151
<i>TABLE 57 THE DRUG DISCOVERY FUNNEL.....</i>		<i>152</i>
	The Drug Discovery Process.....	153
	The Role of In Vitro Toxicology .....	153
	Determining Toxicity Using In Vitro Toxicology.....	153
	Determining Toxicity...(Continued).....	154
	Predictive Ability in Phase III Clinical Trials .....	155
<i>TABLE 58 TYPES OF CLINICAL TRIALS.....</i>		<i>155</i>
	Phase II Clinical Trials .....	155
	Phase III Clinical Trials.....	155
	Lack of Efficacy .....	156
	Trends in Efficacy .....	156
	Increasing Specificity .....	156
	Toxicity Testing.....	157
	The Cons of Chemogenomics .....	157
<i>TABLE 59 CHALLENGES OF CHEMOGENOMICS.....</i>		<i>157</i>
	Drowning in Data.....	157
	Data Analysis .....	158
	Raw Data Analysis .....	158
	Interpretation of the Data .....	159
	How Does This Relate to the Drug Discovery Problem?.....	159
	Alternative Approaches .....	160
<i>TABLE 60 TYPES OF TOXICITY.....</i>		<i>160</i>
	On Target Toxicity.....	160
	Off Target Toxicity.....	161
	BIOLOGICAL SYSTEMS FOR CHEMOGENOMICS.....	161
<i>TABLE 61 COMPARISON BETWEEN THE RODENT AND HUMAN ORGAN SLICES.....</i>		<i>162</i>
	Applicability to Humans .....	162
	Whole Body Metabolism.....	163
	Cost.....	164
	Time Course of the Experiment .....	164
	Facility Requirements .....	164
	Reproducibility.....	164
	EFFECT ON <i>IN VITRO</i> TOXICOLOGY IN PHARMACEUTICALS .....	165
	Summary of Chemogenomics .....	165
	<i>IN VITRO</i> TOXICOLOGY OUTSIDE THE PHARMACEUTICAL INDUSTRY: DERMAL AND OCULAR IRRITATION TESTS.....	165
	THE DRAIZE EYE TEST .....	166
	THE BCOP TEST.....	167
	THE CAM ASSAY .....	168
	MATTEK'S EPIOCULAR AND EPIDERMAL TEST KITS.....	169

INVITRO INTERNATIONAL'S OCULAR AND DERMAL IRRITATION ASSAYS .....	170
INVITRO INTERNATIONAL'S CORROSITEX .....	171
THE FUTURE OF <i>IN VITRO</i> TOXICOLOGY AND <i>IN VIVO</i> TOXICOLOGY .....	171
HOW USEFUL IS SAR (STRUCTURE ACTIVITY RELATIONSHIPS)?.....	172
APPENDIX .....	173
<i>TABLE 62 NUMBER OF ANIMALS USED FOR RESEARCH FROM THE FIRST     REPORTING (FISCAL YEAR 1976 TO PRESENT)</i> .....	173